收费全文 | 2781894篇 |
免费 | 205196篇 |
国内免费 | 4273篇 |
耳鼻咽喉 | 38158篇 |
儿科学 | 90660篇 |
妇产科学 | 74216篇 |
基础医学 | 412354篇 |
口腔科学 | 77239篇 |
临床医学 | 251653篇 |
内科学 | 537795篇 |
皮肤病学 | 61883篇 |
神经病学 | 217019篇 |
特种医学 | 103980篇 |
外国民族医学 | 552篇 |
外科学 | 417845篇 |
综合类 | 58081篇 |
现状与发展 | 12篇 |
一般理论 | 965篇 |
预防医学 | 215811篇 |
眼科学 | 65262篇 |
药学 | 208308篇 |
13篇 | |
中国医学 | 6217篇 |
肿瘤学 | 153340篇 |
2021年 | 22312篇 |
2019年 | 22749篇 |
2018年 | 31479篇 |
2017年 | 23766篇 |
2016年 | 26626篇 |
2015年 | 29976篇 |
2014年 | 42203篇 |
2013年 | 63383篇 |
2012年 | 86752篇 |
2011年 | 91882篇 |
2010年 | 54680篇 |
2009年 | 51686篇 |
2008年 | 86362篇 |
2007年 | 92054篇 |
2006年 | 93109篇 |
2005年 | 89811篇 |
2004年 | 86217篇 |
2003年 | 82744篇 |
2002年 | 80360篇 |
2001年 | 129486篇 |
2000年 | 132671篇 |
1999年 | 111253篇 |
1998年 | 31853篇 |
1997年 | 27821篇 |
1996年 | 28219篇 |
1995年 | 26729篇 |
1994年 | 24601篇 |
1993年 | 23139篇 |
1992年 | 85991篇 |
1991年 | 83937篇 |
1990年 | 81735篇 |
1989年 | 79121篇 |
1988年 | 72757篇 |
1987年 | 71268篇 |
1986年 | 66889篇 |
1985年 | 63833篇 |
1984年 | 47430篇 |
1983年 | 40286篇 |
1982年 | 23659篇 |
1979年 | 43602篇 |
1978年 | 30970篇 |
1977年 | 25862篇 |
1976年 | 24763篇 |
1975年 | 26639篇 |
1974年 | 31887篇 |
1973年 | 30446篇 |
1972年 | 28524篇 |
1971年 | 26944篇 |
1970年 | 25107篇 |
1969年 | 23747篇 |
Methods: Two previously published datasets (n?=?153 and n?=?641, respectively) from outpatient neuropsychological evaluations were used to test Dunham and Denney’s algorithm, and to assess concordance of failure rates with the Test of Memory Malingering and the forced choice measure of the California Verbal Learning Test, two commonly used performance validity tests.
Results: In both datasets, none of the four cutoff scores for failure on the MSVT (70%, 75%, 80%, or 85%) identified a poor validity group with proportionally aligned failure rates on other freestanding measures of performance validity. Additionally, the protocols with probable impairment did not differ from those with poor validity on cognitive measures.
Conclusions: Despite what appeared to be a promising approach to evaluating failure on the easy MSVT subtests when clinical data are unavailable (as recommended in the advanced interpretation program, or advanced interpretation [AI], of the MSVT), the current findings indicate the AI remains the gold standard for doing so. Future research should build on this effort to address shortcomings in measures of effort in neuropsychological evaluations. 相似文献
Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献